Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone857-242-1600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.97 million
Profitability
Miscellaneous
Employees41
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions
What is Spero Therapeutics' stock symbol?
Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."
How were Spero Therapeutics' earnings last quarter?
Spero Therapeutics Inc (NASDAQ:SPRO) announced its earnings results on Thursday, August, 8th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by $0.10. The company had revenue of $2.16 million for the quarter, compared to analysts' expectations of $6.95 million. Spero Therapeutics had a negative net margin of 321.37% and a negative return on equity of 33.84%. View Spero Therapeutics' Earnings History.
When is Spero Therapeutics' next earnings date?
What price target have analysts set for SPRO?
5 analysts have issued twelve-month price targets for Spero Therapeutics' stock. Their predictions range from $9.00 to $28.00. On average, they expect Spero Therapeutics' stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 89.0% from the stock's current price. View Analyst Price Targets for Spero Therapeutics.
What is the consensus analysts' recommendation for Spero Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spero Therapeutics.
What are Wall Street analysts saying about Spero Therapeutics stock?
Here are some recent quotes from research analysts about Spero Therapeutics stock:
- 1. According to Zacks Investment Research, "Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. " (9/12/2019)
- 2. HC Wainwright analysts commented, "916-3963, POS Risk-adj value Full value SPR994 (oral carbapenem) – cUTI 62% $22.87 $36.88 Shares outstanding 18,656 S/O as of SPR741 (IV potentiator) – MDR Gram (-) $3.22 $3.22 Current share price $9.23 Discount rate 14.5% SPR720 (oral treatment) – NTM $1.34 $1.34." (8/12/2019)
- 3. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution, we are reiterating our OW rating and 12-month price target of $27 for SPRO shares. As the company advances its pipeline toward commercialization, we think upward earnings revisions and multiple expansion to levels not reflected in FactSet consensus expectations will drive SPRO’s stock higher. We also like the stock ahead of what we expect to be multiple positive data readouts for 2019+. Anticipated 2019 events include pharmacokinetic data from a lead-in cohort of 70 patients in 2H19 for SPR994 in the cUTI patient population, Phase 1 data for 1 data for SPR720." (5/9/2019)
Has Spero Therapeutics been receiving favorable news coverage?
Media coverage about SPRO stock has trended negative recently, according to InfoTrie. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Spero Therapeutics earned a daily sentiment score of -2.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Spero Therapeutics.
Are investors shorting Spero Therapeutics?
Spero Therapeutics saw a drop in short interest during the month of September. As of September 30th, there was short interest totalling 356,000 shares, a drop of 8.1% from the August 30th total of 387,400 shares. Based on an average trading volume of 40,400 shares, the short-interest ratio is currently 8.8 days. Currently, 3.1% of the shares of the stock are sold short. View Spero Therapeutics' Current Options Chain.
Who are some of Spero Therapeutics' key competitors?
Some companies that are related to Spero Therapeutics include CannTrust (CNTTF), Omeros (OMER), Cara Therapeutics (CARA), Emisphere Technologies (EMIS), ZEALAND PHARMA/S (ZEAL), Rhythm Pharmaceuticals (RYTM), ZIOPHARM Oncology (ZIOP), Vanda Pharmaceuticals (VNDA), Stoke Therapeutics (STOK), Organogenesis (ORGO), Vectura Group (VEGPF), Principia Biopharma (PRNB), Wave Life Sciences (WVE), Cytokinetics (CYTK) and Advanz Pharma (CXRXF).
What other stocks do shareholders of Spero Therapeutics own?
Who are Spero Therapeutics' key executives?
Spero Therapeutics' management team includes the folowing people:
- Mr. Ankit Mahadevia M.D., MBA, Co-Founder, CEO, Pres & Director (Age 38)
- Mr. Joel D. Sendek, CFO, Treasurer & Sec. (Age 52)
- Ms. Cristina Larkin, Chief Operating Officer (Age 49)
- Dr. Thomas R. Parr Jr., Chief Scientific Officer (Age 65)
- Ms. Sharon Klahre, Director of Investor Relations
When did Spero Therapeutics IPO?
(SPRO) raised $75 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.
How do I buy shares of Spero Therapeutics?
Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Spero Therapeutics' stock price today?
One share of SPRO stock can currently be purchased for approximately $11.11.
How big of a company is Spero Therapeutics?
Spero Therapeutics has a market capitalization of $207.31 million and generates $3.97 million in revenue each year. The company earns $-41,660,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. Spero Therapeutics employs 41 workers across the globe.View Additional Information About Spero Therapeutics.
What is Spero Therapeutics' official website?
How can I contact Spero Therapeutics?
Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected]
MarketBeat Community Rating for Spero Therapeutics (NASDAQ SPRO)
MarketBeat's community ratings are surveys of what our community members think about Spero Therapeutics and other stocks. Vote "Outperform" if you believe SPRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
